News

Resunab is a new synthetic oral drug that is a preferential agonist to the CB2 receptor expressed on activated immune cells. The company noted that CB2 activation triggers

FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R) and it targets macrophages and monocytes, which are activated or elevated in multiple disease settings. Five Prime

The 250mg once daily tablets are approved for NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as

Harnessing the patient’s immune system is a promising new avenue in the fight against cancer that continues to garner significant momentum and excitement. Turnstone’s technology platform, Marabex, is

Taptiqom is a preservative-free eye drop solution (in single dose containers) of a fixed dose combination of the prostaglandin analogue tafluprost (15 micrograms/ml) and the beta-blocker timolol (5

"We were looking for a partner who has a clinical trial system that manages clinical data and automates the data capture and laboratory processes in Phase I units,"

Under the agreement, EyeGate will receive an upfront cash payment, development-based milestone payments related to the completion of development for the indication of anterior uveitis and an approval-based

Purchasers in the private placement (comprised of 33 institutional investors in China) have agreed to a lock-up period of 12 months, the same as for STA and WuXi

Prestalia, a first fixed-dose combination of perindopril arginine and amlodipine besylate, is now available by prescription for use in patients whose blood pressure is not adequately controlled on